Allogeneic hematopoietic cell transplantation for plasma cell myeloma can lead to graft-vs-myeloma immunity and long-term survivorship, but limited efficacy and associated toxicities have prevented its widespread use. Cellular immunotherapies seek to induce more specific, reliable and potent antimyeloma immune responses with less treatment-related risk than is possible with allogeneic transplantation. Strategies under development include infusion of vaccine-primed and ex vivo expanded/costimulated autologous T cells after high-dose melphalan, genetic engineering of autologous T cells with receptors for myeloma-specific epitopes, administration of DC/plasma cell fusions and administration expanded marrow-infiltrating lymphocytes. In addition, novel immunomodulatory drugs such as inhibitors of the programmed death-1 T cell regulatory pathway may synergize with cellular immunotherapies.
INTRODUCTION
Survival of patients with plasma cell myeloma has improved since the incorporation of high-dose melphalan and autologous hematopoietic cell transplantation (auto-HCT), thalidomide analogs and proteasome inhibitors into routine care. Despite these advances, plasma cell myeloma remains incurable, highlighting the need for new approaches. In this review, we discuss the rationale for cellular immunotherapy in plasma cell myeloma, which is rooted in the clinical experience of treating plasma cell myeloma with allogeneic hematopoietic cell transplantation (allo-HCT) (Table 1) , and review the clinical experience with novel cellular immunotherapy strategies, focusing on recently published and ongoing clinical research (Table 2) .
ALLO-HCT AS CELLULAR IMMUNOTHERAPY
Allo-HCT is a form of cellular immunotherapy, in which the donor immune system is nonspecifically unleashed on the recipient's malignancy. Allo-HCT in plasma cell myeloma has been the subject of extensive clinical investigation. Early efforts made use of myeloablative conditioning regimens, which have largely been abandoned due to unacceptable toxicity. There nonetheless has remained interest in incorporating allo-HCT into treatment plans based on consistent findings of long-term disease control in a minority of patients. A full discussion of this literature is beyond the scope of this review but can be found elsewhere. 1, 2 We will focus on recent efforts to couple nonmyeloablative allo-HCT to auto-HCT because a single auto-HCT has become a standard-ofcare for younger patients based on two randomized trials showing survival benefit compared with standard-dose chemotherapy. 3, 4 On the basis of promising results of phase II studies, along with data that emerged in parallel suggesting that a second auto-HCT might improve outcomes compared with a single auto-HCT, 1, 2, 5, 6 five prospective trials assigning more than 1500 patients after an initial auto-HCT to either a second auto-HCT (auto-auto) or nonmyeloablative allo-HCT (auto-allo) were undertaken in both Europe and North America and have reported results in the last 6 years. [7] [8] [9] [10] [11] [12] The results are summarized in Table 1 . Assignment of treatment arm in these trials was based on the availability of a suitable HLA-matched sibling rather than true randomization; this strategy may have introduced bias with the potential to influence results in either direction. All accrued before the widespread use of novel agents (thalidomide and its analogs, proteasome inhibitors) in initial therapy and contemporary definitions of high-risk plasma cell myeloma. Two of the five studies 8, 10, 12 showed significant OS and PFS/EFS advantages in the auto-allo arms, whereas three showed no difference in survival outcomes, 7, 9, 11 including the largest and most recently reported study. 11 Interpretation of the two trials that showed improved outcomes with an auto-allo approach is complicated by failure of many subjects assigned to auto-auto to complete both auto-HCTs (56 (ref. 8) and 42% (ref. 10) ) and, in the case of Bruno et al., 8 use of a lower melphalan dose (100-140 mg/m 2 in a subset of patients) in the auto-auto arm compared with the auto-allo arm. In contrast, in BMT-CTN 0102, 11 the most recently reported and largest study, 82% of patients completed two auto-HCTs in the auto-auto arm with a melphalan dose of 200 mg/m 2 . No difference in PFS, progression or relapse, or OS was seen after median follow-up of 36 months, though TRM was higher in the allo-allo group (Po0.0001) (Figure 1) . Consequently, although a survival benefit may emerge with longer follow-up, allo-HCT is not routinely employed at present in the care of plasma cell myeloma patients.
Graft-vs-myeloma (GVM) effect Despite the lack of consistent OS benefit, these trials provide indirect evidence of a GVM effect that may lead to long-term disease control in a minority of patients. In the high-risk subgroup in BMT-CTN 0102 (defined as b-2-microglobulin concentration 44 mg/L at diagnosis or deletion of chromosome 13 on metaphase karyotyping), there was a lower cumulative incidence of relapse or progression at a median follow-up of 3 years in the Table 1 . Summary of trials comparing tandem auto-HCT to auto-HCT followed by reduced-intensity allogeneic transplantation Garban et al. 7 Bruno et al. 8 Giaccone et al.
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Bjorkstrand et al. 10 Krishnan et al. auto-allo arm compared with the auto-auto arm, but this difference was not statistically significant (38% vs 57%, P ¼ 0.079). 11 In addition, among the 54% of standard-risk patients in the allo-allo arm who developed chronic GVHD, there was a 56% reduction in the relative risk relapse or progression compared with those who did not develop chronic GVHD (P ¼ 0.008), a phenomenon also observed in earlier cohorts. [13] [14] [15] [16] In addition, plateaus in PFS or relapse in the auto-allo arms that were not seen in the auto-auto arms were reported in three of the other trials. [8] [9] [10] Taken together, these data suggest that allo-HCT exerts a GVM effect, but the clinical benefit is outweighed by treatment-related toxicity.
DLI
Responses to DLI after allo-HCT provide more direct evidence for a T-cell mediated GVM effect. Case reports of responses to DLI emerged in the late 1990s and included reports of repeated response to sequential rounds of DLI and molecular remissions [17] [18] [19] ( Figure 2 ). Larger reports subsequently documented response rates between 30 and 50% and strong correlations between response and the induction of GVHD. 20, 21 In a small group of patients treated at Dana Farber Cancer Institute with T-cell depleted allo-HCT followed by prophylactic DLI, 22 DLI accelerated immune reconstitution as indicated by increased quantities of circulating B-cells, accelerated recovery of T-cell repertoire complexity, and restoration of T-cell neogenesis compared with patients who did not receive DLI. 23 Further work by the same group demonstrated the development of myelomaspecific Abs and CD8 þ T-cell clones following DLI that temporally correlated with the onset of clinical response. [24] [25] [26] [27] Enhancement by novel agents Experience with the novel agents thalidomide, lenalidomide and bortezomib after allo-HCT suggests an ability of these drugs to modulate the graft-vs-host immune reactions. Thalidomide and lenalidomide both seem to have stimulatory effects on GVHD and GVM. [28] [29] [30] [31] Though randomized studies have not been performed, lenalidomide seems to augment the efficacy of DLI in progressive/ relapsed disease after allo-HCT, 31 but administration early (3 months) after allo-HCT leads to intolerable levels of GVHD. Abbreviation: PD-1 ¼ programmed death-1.
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Bortezomib has a complicated immunomodulatory profile and has both immunosuppressive and immune-sensitizing properties. 32 In one report, 27/37 patients with relapsed/progressive disease after non-myeloablative SCT responded to bortezomib despite corresponding improvements in GVHD. 33 It is uncertain whether the myeloma responses observed in this study were due to immunomodulatory or directly cytotoxic properties of bortezomib.
In summary, these data collectively provide evidence that manipulation of the immune system with nonspecific techniques such as allo-HCT, DLI, and immunomodulatory medication can induce favorable disease responses. The toxicity that has prevented the demonstration of a net clinical benefit with these approaches in phase-III trials provides a rationale for the development of more targeted cellular immunotherapies for plasma cell myeloma.
AUTOLOGOUS TRANSPLANTATION AS A PLATFORM FOR CELLULAR IMMUNOTHERAPY
The traditional rationale for auto-HCT is the cytotoxic effect of myeloablative doses of chemotherapy. Several lines of evidence suggest that auto-HCT also has immunomodulatory properties.
GVHD has been observed after auto-HCT, suggesting a transient loss of self-tolerance in some patients following myeloablative chemotherapy. The skin and gastrointestinal tract are the most commonly affected organs. One early series describing skin involvement reported an incidence of 8%. 34 In a more recently reported cohort of 681 auto-HCT patients, in which gastrointestinal autologous GVHD was prospectively investigated in any patient with unexplained upper or lower gastrointestinal symptoms, the reported incidence was 13% and consisted mostly of mild upper-gastrointestinal symptoms. 35 The pathology is indistinguishable from that of acute GVHD of allo-HCT. 36 The clinical course is generally benign and, if treatment is necessary, responsive to steroids, though severe, fatal cases have been reported. 37 The syndrome is slightly more common in syngeneic transplants, where parity among female donors is a significant risk factor. 38 One group identified altered expression of certain cellsurface molecules and transcription factors (decreased CXCR4, increased CD130, increased GATA2) among CD34 þ progenitors in the grafts of patients who developed autologous GVHD compared with contemporaneously treated, unaffected controls. 39 Another study has shown that T-cell and humoral immune responses to myeloma-specific Ags are more common after autologous and syngeneic transplant than in untreated myeloma patients. 40 No studies have associated the development of autologous/ syngeneic GVHD with protection from relapse. This may be due to the lack of subsequent chronic GVHD in patients who develop acute autologous GVHD, as acute GVHD alone after allo-HCT for plasma cell myeloma does not seem to be associated with protection from relapse. 16 Further evidence for an immunomodulatory effect of auto-HCT comes from a series of observations correlating accelerated lymphocyte reconstitution after auto-HCT with improved disease control. Building on prior observations that lymphocyte reconstitution following allo-HCT was associated with improved disease control, 41, 42 Porrata et al. 43 observed improved OS and PFS in patients with higher absolute lymphocyte counts at day 15 after auto-HCT in patients with plasma cell myeloma and non-Hodgkin's lymphoma. The survival differences were pronounced; for plasma cell myeloma, median OS was 33 vs 12 months (Po0.0001), and PFS was 16 vs 8 months (Po0.0001) (Figure 3 ). There was no association between the post-transplant absolute lymphocyte count and graft characteristics such as CD34 þ cell dose, nucleated cell dose, or mononuclear cell dose, post-transplant ANC or pretransplant therapy. In the plasma cell myeloma subset, among a host of other clinical prognostic factors with significant impacts on OS and PFS in univariate analysis, the correlation between day 15 ALCX500 and survival persisted on multivariate analysis (relative risk for death 0.176, P ¼ 0.0001; relative risk for progression 0.275, P ¼ 0.0006). These findings were replicated by others [44] [45] [46] [47] and also observed following auto-HCT for diseases other than myeloma and NHL, including Hodgkin's lymphoma, 48 AML 49 and amyloidosis. 50 The peripheral ALC before stem cell harvest and the lymphocyte dose in the graft, 51 and the NK-cell dose in the graft 52 in particular, are strongly associated with posttransplant ALC. When various lymphocyte subsets were measured prospectively in grafts and peripheral blood after auto-HCT for impact on survival in non-Hodgkin's lymphoma patients, the infused NK-cell dose and the postauto-HCT NK-cell count emerged as the only independent predictors of OS in a multivariate analysis considering CD4, CD8 and B-cell subsets. 53 Infusion of activated autologous T-cells These data collectively suggest that the period following auto-HCT is a window, in which myeloma-induced immune tolerance (and self-tolerance in general) might be compromised. In the subset of patients who receive higher lymphocyte doses (and in particular NK-cell doses) with their autografts, the observed protection from relapse might represent a unique sensitivity after auto-HCT to the reconstituting immune system. Yet the adaptive immune system is notoriously impaired both quantitatively and qualitatively after auto-HCT, as manifest by the increase risk of infection, poor response to vaccination and low Ig levels that persist for monthsto-years. 54 This raises the appealing possibility that cellular immunotherapies that foster immune reconstitution might be most effective when coupled with auto-HCT.
With this in mind, a series of studies were carried out at our institution in collaboration with the University of Maryland to optimize delivery of ex vivo-expanded and costimulated, autologous T-cells (hereafter referred to as activated T-cells) after auto-HCT towards the goal of developing auto-HCT as a platform for cellular immunotherapy for plasma cell myeloma. The rationale for combining auto-HCT with activated T-cell infusion was that accelerating immune reconstitution might counter post-transplant immunodeficiency and hence reduce infectious complications, improve tumor immunity and permit improved responses to both standard-of-care vaccines and perhaps tumor vaccines. This approach was enabled by advances in T-cell culture methods, namely coculture of T-cells with Ab-coated microbeads to provide simultaneous in vitro activation (anti-CD3) and costimulatory (anti-CD28) signals, 55 that allowed generation of cell doses on the order of 10 10 cells even in patients who had been extensively pretreated with cytotoxic chemotherapy. Clinically this method was first employed in a phase I trial to reconstitute T cells in HIV-infected patients 56 and later shown to be feasible in the setting of auto-HCT in phase I trials with refractory non-Hodgkin's B-cell lymphoma patients 57 and imatinib-and IFN-refractory CML patients with no suitable allogeneic donor. 58 In these latter trials, T-cells generated from a mononuclear cell apheresis before stem cell mobilization were infused on day 14 after auto-HCT.
This experience led to a randomized trial in plasma cell myeloma patients testing whether activated T-cells after auto-HCT could improve responses to the pneumococcal conjugate vaccine. 59 Forty-two patients were randomized in 2 Â 2 fashion to receive T-cells on day 12 or 100 after auto-HCT and to receive post-transplant pneumococcal vaccine (2 doses) with or without an initial dose before mononuclear cell collection. Serologic responses consistent with clinical immunity correlated temporally with T-cell infusion and only occurred in patients receiving a precollection priming dose, which the authors hypothesize allowed in vivo T-cell 'priming' before expansion/costimulation (Figure 4) . Moreover, only patients who received the priming dose and early T-cell infusion on day 12 responded to the booster vaccinations on day 30 and 90. T-cell counts and vaccine-specific responsiveness were all superior in the group receiving earlier T-cell infusions. Activated T-cell infusions were well tolerated; a self-limited rash in a minority of patients was the only significant toxicity. Therefore, activated T-cell infusion after auto-HCT is safe and feasible in plasma cell myeloma patients, facilitates T-cell immune reconstitution, and, when coupled with precollection priming by an effective vaccine, enables specific humoral immune responses that can be boosted with additional post-infusion vaccinations.
Tumor vaccine strategies A second trial employed activated T-cells in a group of 54 patients with plasma cell myeloma undergoing auto-HCT with the objective of (1) testing the safety and feasibility of infusing activated T cells earlier (day 2) after auto-HCT to take advantage of , and T-cell depleted, TBI/thiopeta/CY/ATG-conditioned allo-HCT from a matched, unrelated donor (MUD BMT) are depicted. This was followed by progression through an initial DLI (Donor PB cells) followed by a durable response corresponding to a second DLI that was accompanied by onset of acute and later chronic GVHD. the cytokine milieu induced by lymphopenia after auto-HCT that favors T-cell proliferation 60 and (2) determining whether a tumor vaccine comprised of HLA-A2-restricted peptides derived from the tumor Ags telomerase and survivin could elicit immune responses and anti-myeloma effects when coupled with activated T cells. 61, 62 Additionally, a subset of the patients on this study received seasonal influenza vaccine on either a priming or non-priming schedule to confirm the findings from the pneumococcal vaccination study discussed above regarding the ability of in vivo priming to improve vaccine responses after activated T-cell infusion. Biologic assignment based on carriage of an HLA-A2 genotype determined whether patients received the telomerase/survivin vaccine, which was delivered in an initial priming dose before collection and in three post-HCT boosting doses. T-cell doses in this trial were also roughly fivefold higher compared with the prior trials due to interim advances in culture methods. This earlier infusion of a larger quantity of T-cells was associated with a syndrome of watery diarrhea and/or rash in 16% of patients. Colon biopsies of patients with the diarrhea syndrome revealed grade 2-3 GVHD. These autoimmune reactions were more common in patients receiving the telomerase-based vaccine, but they were not exclusive to this arm. Lymphocyte reconstitution was substantially accelerated compared with the prior activated T-cell trials, and lymphocyte subset analysis showed a strong bias in favor of effector over regulatory T cells (T regs ). Univariate analysis of factors influencing EFS found that high CD4/CD8 ratio and low fraction of T regs correlated with improved EFS. Analysis of influenza titers confirmed that vaccineprimed, activated T-cells augment vaccine-specific immune responses. 63 Thirty-six percent of patients who received the telomerase/survivin vaccine developed vaccine-specific immune responses, a far lower immunologic response rate than was observed with influenza and pneumococcal vaccination. Patients receiving the vaccination had inferior EFS after 2 years (25% vs 65%, P ¼ 0.0068), though this was most likely due to more frequent use of thalidomide maintenance in the unvaccinated arm; this study was conducted between two cooperating centers before maintenance therapy was routinely employed after auto-HCT, and the center with the higher proportion of HLA-A2-positive patients (and hence more vaccine recipients) also coincidentally had not adopted thalidomide maintenance in routine practice.
The results of these trials demonstrate that activated T-cells can be safely deployed with auto-HCT to accelerate immune reconstitution, bias reconstitution towards effector T-cell populations that may control disease, and generate immune responses to vaccines against infections and tumor Ags. Efforts are currently underway to investigate the safety and efficacy of other tumor vaccines in combination with activated T-cells surrounding auto-HCT. A phase II trial is currently underway combining activated T-cells with a peptide vaccine against MAGEA3 (clinicaltrials.gov identifier NCT01245673), a cancer-testis Ag expressed in B55% of plasma cell myeloma, and which commonly elicits a specific humoral immune response after allo-HCT. 64 A separate singlearm study is assessing a MAGEA3-based vaccine after auto-HCT without activated T-cells (clinicaltrials.gov identifier NCT01380145). An additional approach in development involves a idiotype vaccine, wherein each subject's particular paraprotein is used to create a personalized vaccine to be administered with auto-HCT and activated T-cells (clinicaltrials.gov identifier NCT01426828).
T-cell genetic engineering
The efforts discussed so far utilize priming vaccination to confer specificity onto activated T cells. An alternative approach is to 59 who received 7-valent pneumococcal conjugate vaccine (PCV) and autologous T-cells on one of four schedules: groups 1 (square symbol) and 2 (circle symbol) received PCV before T-cell collection, whereas groups 3 (upside-down triangle symbol) and 4 (triangle symbol) received no priming PCV; groups 1 and 3 received autologous T cells before post-auto-HCT PCV boosters, whereas groups 2 and 4 received autologous T cells after post-auto-HCT PCV boosters.
confer specificity directly by transducing activated T-cells with genes encoding T-cell receptors specific for the Ag of interest. This approach is enabled by advances in methods of T-cell gene transfer and T-cell receptor engineering. 65 A trial is underway employing activated T-cells genetically engineered to express T-cell receptors specific for NY-ESO-1 and LAGE-1, which are also cancer-testis Ags expressed in B50% of plasma cell myeloma, 64, 66 with auto-HCT (clinicaltrials.gov identifier NCT01352286). Results of these ongoing investigations will help determine whether the minimal-disease state and unique immune context induced by auto-HCT can be exploited with tumor-directed activated T-cells to generate clinically meaningful immunity that protects against relapse.
DC-BASED APPROACHES
There has been intense interest in the use of DC to stimulate clinically meaningful immune responses against cancer with the appreciation of these cells' important role in Ag presentation, determination of T-cell polarization between effector function or anergy, and modulation of cancer-induced immune tolerance. 67 The first and only FDA-approved cellular immunotherapy for cancer is a DC-based vaccine for prostate cancer, sipuleucel-T (marketed as Provenge), which modestly prolonged survival in castration-resistant prostate cancer in a large, randomized trial when compared with placebo. 68 Despite the improvement in OS, there was surprisingly no improvement in PFS. Sipuleucel-T is manufactured by incubating a preparation of APC, including DC, from peripheral blood leukapheresis product with a prostate cancer Ag followed by i.v. infusion. The vaccine is administered three times over 4 weeks. A similar approach was taken in a singlearm phase-II trial of plasma cell myeloma patients, in which autologous serum containing monoclonal protein was incubated with an APC preparation and administered intravenously; four doses were administered over 16 weeks. 69 The patients had all undergone auto-HCT at least 60 days prior and had not progressed at the time of enrollment. Immunologic end points were not reported, but the clinical results were compared with those of a contemporaneously treated cohort with similar clinical characteristics. Like the sipuleucel-T study, there was no difference in time-to-progression or PFS, but there was significantly longer median OS in the vaccinated group (5.3 vs 3.4 years, P ¼ 0.02). This may indicate an impact of DC vaccination on the response to subsequent therapy or some other component of the pathophysiology not captured in the disease measurements currently used to assess progression in clinical practice.
DC fusions
Fusion of DC with cancer cells is another strategy that has been investigated and is being developed in plasma cell myeloma. In this approach, autologous cancer cells are fused to either autologous or allogeneic DC, which allows Ag presentation along MHC class I and II pathways, leads to more potent T-cell responses than are observed with other mechanisms of Ag loading, and has produced promising results in preclinical studies and early phase clinical trials in solid tumors. [70] [71] [72] [73] [74] Applied to plasma cell myeloma, an initial study demonstrating the manufacturing feasibility and ex vivo immunogenicity of plasma/DC fusions 75 led to a phase I study, in which 17 heavily pretreated patients (mean number of prior regimens ¼ 4; 14/17 patients had previously received auto-HCT) received three s.c. doses at 3-week intervals of an autologous plasma/DC vaccine with GM-CSF. The main toxicity was grade 1-2 injection-site reactions, which on biopsy consisted mostly of a CD8 þ T-cell infiltrate. Vaccination was associated with significant increases in myeloma-specific T-cell responsiveness in a majority of patients. New myeloma-specific humoral responses were also detected in a minority of patients. Eleven of 16 evaluable patients demonstrated stable disease, 3 of whom exhibited long-term stability between 12 and 41 months. This has led to an ongoing study, discussed below, combining programmed death-1 (PD-1) blocking Ab with DC fusion vaccination in plasma cell myeloma patients.
MARROW-INFILTRATING LYMPHOCYTES
As the malignant plasma cells of plasma cell myeloma reside mainly in the BM, the BM of plasma cell myeloma patients may be enriched for T-cells specific for myeloma Ags. Marrow-infiltrating lymphocytes from plasma cell myeloma patients exhibit significantly enhanced proliferation and myeloma-specific cytotoxicity in response to ex vivo activation and costimulation compared to peripheral blood lymphocytes. 76 These observations have led to an ongoing clinical trial in which marrow-derived, activated T-cells are re-infused on day þ 3 after auto-HCT (clinicaltrials.gov identifier NCT00566098).
COMBINING CELLULAR AND PHARMACOLOGIC IMMUNOTHERAPY Ag recognition by T-cells on APCs can result either in T-cell activation or adoption of an immunosuppressive (for example, T reg ) phenotype. A host of cell-cell contacts referred to as 'immune checkpoints' has been elucidated in recent years that collectively determine the quality and amplitude of T-cell responses to Ag recognition. Immune checkpoints seem to have a physiologic role in balancing immune surveillance and self-tolerance. Exploitation of immune checkpoints has emerged as an important mechanism, by which cancers evade the immune system, which has prompted the development of multiple drugs targeting these pathways. 77 Ipilimumab was the first immune checkpoint modulator to be FDA-approved; ipilimumab inhibits CTLA-4, a negative regulator of T-cell activation, and improves OS in metastatic melanoma. 78 The T-cell-surface protein PD-1 is another inhibitor of T-cell activation, and several MoAbs against PD-1 and its ligand are in clinical development and have yielded impressive results in phase-I trials in solid tumors. [79] [80] [81] While these agents nonspecifically promote T-cell activation, they may synergize with more specific cellular immunotherapies. Indeed, Rosenblatt et al., 82 who reported the favorable immune responses to the plasma/dendritic fusion vaccine discussed above, identified PD-1-ligand on plasma cell myeloma and high levels of PD-1 expression on T-cells from myeloma patients compared with normal controls. Ex vivo treatment of their fusion vaccine with the PD-1 blocking Ab CT-011 enhanced T-cell responses, 82 which has prompted clinical trial that is now underway combining dendritic/plasma cell fusion vaccination with CT-011 therapy (clinicaltrials.gov identifier NCT01067287).
CONCLUSION
While the success of allogeneic transplantation for certain hematologic malignancies demonstrates the capacity of the immune system to cure cancer, the experience of allogeneic transplantation for plasma cell myeloma highlights the need for more targeted and less toxic approaches. Significant challenges remain for investigators at both the bench and bedside to the development of efficacious cellular immunotherapies for plasma cell myeloma. At the bench, a full understanding of the mechanisms underlying myeloma-induced immune tolerance is critical. The identification of PD-1-ligand on myeloma plasma cells discussed above is an important first step, as is the recent characterization of myeloid-derived suppressor cells in plasma cell myeloma patients. 83 At the bedside, clinical investigators will need to identify in which clinical settings cellular immunotherapies will be most effective and how to integrate them with the rapidly expanding array of targeted agents available for plasma cell myeloma. Drawing on the experience of allo-HCT for leukemia, it is tempting to speculate that cellular immunotherapies will be most effective in minimal residual disease settings, though the recently reported demonstration that gene-modified T-cells targeting CD19 can induce deep remissions in CLL patients with heavy tumor burdens 84 indicates that a minimal-disease state is not a prerequisite for effective cellular immunotherapy. Despite these challenges, the progress described in this review is cause for optimism that advances in cellular immunotherapy will lead to better outcomes for patients with plasma cell myeloma.
